Alle verbonden artikelen

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Auteurs : Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO
Jaar : 2013
Journal : Eur. J. Cancer
Volume : 49(15)
Pagina's : 3219-28

How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.

Auteurs : Pinto AC, de Azambuja E, Piccart-Gebhart M
Jaar : 2013
Journal : Breast Care (Basel)
Volume : 8(4)
Pagina's : 264-269

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

Auteurs : Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber Rd, Piccart-Gebhart M, Cameron D
Jaar : 2013
Journal : Lancet Oncol
Volume : 14(3)
Pagina's : 244-8

The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.

Auteurs : Klastersky J, Raftopoulos H, Rapoport B
Jaar : 2013
Journal : Support Care Cancer
Volume : 21(6)
Pagina's : 1793-5

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Auteurs : Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M
Jaar : 2013
Journal : Breast
Volume : 22 Suppl 2
Pagina's : S152-5

Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study.

Auteurs : Kenis C, Bron D, Libert Y, Decoster L, Van Puyvelde K, Scalliet P, Cornette P, Pepersack T, Luce S, Langenaeken C, Rasschaert M, Allepaerts S, Van Rijswijk R, Milisen K, Flamaing J, Lobelle JP, Wildiers H
Jaar : 2013
Journal : Ann Oncol
Volume : 24(5)
Pagina's : 1306-12

Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis.

Auteurs : Azim HA, Singhal S, Ignatiadis M, Desmedt C, Fumagalli D, Veys I, Larsimont D, Piccart-Gebhart M, Michiels S, Sotiriou C
Jaar : 2013
Journal : PLoS One
Volume : 8(4)
Pagina's : e62451

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Auteurs : Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M
Jaar : 2013
Journal : Lancet Oncol
Volume : 14(8)
Pagina's : 760-8

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).

Auteurs : Ades F, de Azambuja E, Daugaard G, Ameye L, Moulin C, Paesmans M, De Jong D, Decoster L, De Greve J, Ismael G, Møller AK, Piccart-Gebhart M, Awada A
Jaar : 2013
Journal : J Chemother
Volume : 25(4)
Pagina's : 239-46

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.

Auteurs : Stuurman FE, Voest EE, Awada A, Witteveen PO, Bergeland T, Hals PA, Rasch W, Schellens JH, Hendlisz A
Jaar : 2013
Journal : Invest New Drugs
Volume : 31(4)
Pagina's : 959-66

Planning cancer control in Latin America and the Caribbean.

Auteurs : Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, Louis JS, Villarreal-Garza C, Unger-Saldaña K, Ferreyra M, Debiasi M, Liedke PE, Touya D, Werutsky G, Higgins M, Fan L, Vasconcelos C, Cazap E, Vallejos C, Mohar A, Knaul F, Arreola H, Batura R, Luciani S, Sullivan R, Finkelstein D, Simon S, Barrios C, Kightlinger R, Gelrud A, Bychkovsky V, Lopes G, Stefani S, Blaya M, Souza FH, Santos FS, Kaemmerer A, de Azambuja E, Zorilla AF, Murillo R, Jeronimo J, Tsu V, Carvalho A, Gil CF, Sternberg C, Dueñas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Gabús R, Ribeiro R, Knust R, Ismael G, Rosenblatt E, Roth B, Villa L, Solares AL, Leon MX, Torres-Vigil I, Covarrubias-Gomez A, Hernández A, Bertolino M, Schwartsmann G, Santillana S, Esteva F, Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G
Jaar : 2013
Journal : Lancet Oncol
Volume : 14(5)
Pagina's : 391-436

Imbalance between supply and need of medical oncologists in Belgium

Auteurs : Dhondt V, Benahmed A, De Wever L, Dirix L, de Valeriola D
Jaar : 2013
Journal : Belgian J Medical Oncology
Volume : 7(2)
Pagina's : 38-45

Understanding the factors associated with the surgical management of early breast cancer.

Auteurs : Youssef OZ, Azim HA
Jaar : 2013
Journal : Gland Surg
Volume : 2(1)
Pagina's : 4-6

Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer.

Auteurs : Pugliano L, de Azambuja E
Jaar : 2012
Journal : Onkologie
Volume : 35(9)
Pagina's : 476-8

Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC).

Auteurs : Klastersky J, Awada A
Jaar : 2012
Journal : Crit Rev Oncol Hematol
Volume : 81(1)
Pagina's : 49-57

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.

Auteurs : Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, Piccart-Gebhart M
Jaar : 2012
Journal : J Oncol
Volume : 2012
Pagina's : 417673

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Auteurs : Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber Rd, Piccart-Gebhart M
Jaar : 2012
Journal : Lancet
Volume : 379(9816)
Pagina's : 633-40

Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).

Auteurs : Azim HA, Metzger-Filho O, de Azambuja E, Loibl S, Focant F, Gresko E, Arfi M, Piccart-Gebhart M
Jaar : 2012
Journal : Breast Cancer Res. Treat.
Volume : 133(1)
Pagina's : 387-91

Dissecting the heterogeneity of triple-negative breast cancer.

Auteurs : Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M
Jaar : 2012
Journal : J. Clin. Oncol.
Volume : 30(15)
Pagina's : 1879-87

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

Auteurs : Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F
Jaar : 2012
Journal : Ann Oncol
Volume : 23 Suppl 7
Pagina's : vii155-66